JPWO2022007713A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022007713A5 JPWO2022007713A5 JP2023501231A JP2023501231A JPWO2022007713A5 JP WO2022007713 A5 JPWO2022007713 A5 JP WO2022007713A5 JP 2023501231 A JP2023501231 A JP 2023501231A JP 2023501231 A JP2023501231 A JP 2023501231A JP WO2022007713 A5 JPWO2022007713 A5 JP WO2022007713A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- virus
- cell
- infection
- coronavirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 31
- 241000711573 Coronaviridae Species 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 11
- 208000015181 infectious disease Diseases 0.000 claims 11
- 241000700605 Viruses Species 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 claims 8
- 229960004267 taurolidine Drugs 0.000 claims 8
- 206010035664 Pneumonia Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000025721 COVID-19 Diseases 0.000 claims 4
- 241001678559 COVID-19 virus Species 0.000 claims 4
- 241000287828 Gallus gallus Species 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 241000712461 unidentified influenza virus Species 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 2
- 241000282465 Canis Species 0.000 claims 2
- 206010011224 Cough Diseases 0.000 claims 2
- 241000283073 Equus caballus Species 0.000 claims 2
- 241000282324 Felis Species 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 2
- 241000282414 Homo sapiens Species 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 241000712431 Influenza A virus Species 0.000 claims 2
- 241000713196 Influenza B virus Species 0.000 claims 2
- 241000713297 Influenza C virus Species 0.000 claims 2
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 2
- 241000009328 Perro Species 0.000 claims 2
- 201000007100 Pharyngitis Diseases 0.000 claims 2
- 241000288906 Primates Species 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims 2
- 241000283984 Rodentia Species 0.000 claims 2
- 206010053879 Sepsis syndrome Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 241000282898 Sus scrofa Species 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 230000002745 absorbent Effects 0.000 claims 2
- 239000002250 absorbent Substances 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 241001493065 dsRNA viruses Species 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 230000001146 hypoxic effect Effects 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 210000001161 mammalian embryo Anatomy 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 201000004193 respiratory failure Diseases 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 208000026425 severe pneumonia Diseases 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 230000029812 viral genome replication Effects 0.000 claims 2
- 239000000080 wetting agent Substances 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010638926.9A CN111658652A (zh) | 2020-07-06 | 2020-07-06 | 牛磺罗定在制备抗冠状病毒药物中的应用 |
| CN202010638926.9 | 2020-07-06 | ||
| CN202010639186.0A CN111773227A (zh) | 2020-07-06 | 2020-07-06 | 牛磺罗定在制备抗新型冠状病毒SARS-CoV-2药物中的应用 |
| CN202010639186.0 | 2020-07-06 | ||
| CN202010994928.1 | 2020-09-21 | ||
| CN202010994928.1A CN112641789A (zh) | 2020-09-21 | 2020-09-21 | 一种化合物在治疗和预防新型冠状病毒和流感病毒药物方面的应用 |
| PCT/CN2021/104197 WO2022007713A1 (zh) | 2020-07-06 | 2021-07-02 | 牛磺罗定在抗病毒中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533041A JP2023533041A (ja) | 2023-08-01 |
| JPWO2022007713A5 true JPWO2022007713A5 (de) | 2023-11-22 |
Family
ID=77998103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501231A Pending JP2023533041A (ja) | 2020-07-06 | 2021-07-02 | ウイルスに対するタウロリジンの使用 |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2023533041A (de) |
| CN (1) | CN113491700B (de) |
| BR (1) | BR112023000308A2 (de) |
| WO (1) | WO2022007713A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114917285B (zh) * | 2022-04-06 | 2023-06-23 | 军事科学院军事医学研究院军事兽医研究所 | 一种多糖化合物在预防和治疗呼吸道病毒感染药物中的应用 |
| CN115350181B (zh) * | 2022-08-17 | 2023-12-29 | 吉林大学 | 一种小分子化合物在制备抗病毒感染的药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6608051B1 (en) * | 1999-03-12 | 2003-08-19 | Medpointe Healthcare Inc. | Compositions and methods for treating blood |
| EP2699572B1 (de) * | 2011-04-21 | 2016-08-10 | Origenis GmbH | Heterocyclische verbindungen als kinasehemmer |
| CN110776479A (zh) * | 2014-12-19 | 2020-02-11 | 盖斯特里希医药公司 | *噻嗪样化合物、其制备方法和用途 |
| US20170056333A1 (en) * | 2015-08-31 | 2017-03-02 | Cormedix Inc. | Delivery of active agents using nanofiber webs |
| CN112641789A (zh) * | 2020-09-21 | 2021-04-13 | 军事科学院军事医学研究院军事兽医研究所 | 一种化合物在治疗和预防新型冠状病毒和流感病毒药物方面的应用 |
| CN111658652A (zh) * | 2020-07-06 | 2020-09-15 | 长春迈灵生物工程有限公司 | 牛磺罗定在制备抗冠状病毒药物中的应用 |
| CN111773227A (zh) * | 2020-07-06 | 2020-10-16 | 长春迈灵生物工程有限公司 | 牛磺罗定在制备抗新型冠状病毒SARS-CoV-2药物中的应用 |
| CN111617086A (zh) * | 2020-07-06 | 2020-09-04 | 长春迈灵生物工程有限公司 | 牛磺罗定在制备抗hpv病毒药物中的应用 |
| CN111671758A (zh) * | 2020-07-06 | 2020-09-18 | 长春迈灵生物工程有限公司 | 牛磺罗定在制备抗hiv病毒药物中的应用 |
-
2021
- 2021-07-02 CN CN202110752333.XA patent/CN113491700B/zh active Active
- 2021-07-02 BR BR112023000308A patent/BR112023000308A2/pt unknown
- 2021-07-02 JP JP2023501231A patent/JP2023533041A/ja active Pending
- 2021-07-02 WO PCT/CN2021/104197 patent/WO2022007713A1/zh active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101440629B1 (ko) | 바이러스 감염을 시스테아민 화합물로 치료하는 물질들 및방법들 | |
| JP6567781B2 (ja) | ウイルス感染症の治療用チアゾリド化合物 | |
| US9168236B2 (en) | Methods and pharmaceutical compositions for inhibiting influenza viruses replication | |
| Dal Pozzo et al. | Antiviral chemotherapy in veterinary medicine: current applications and perspectives | |
| WO2022007713A1 (zh) | 牛磺罗定在抗病毒中的应用 | |
| WO2021175224A1 (zh) | 抗rna病毒药物及其应用 | |
| Smyk et al. | Favipiravir in the battle with respiratory viruses | |
| CN101340902B (zh) | 用半胱胺化合物处理病毒感染的材料和方法 | |
| JPWO2022007713A5 (de) | ||
| ES2937145T3 (es) | Azelastina como tratamiento antiviral | |
| JP2010528053A (ja) | インフルエンザ感染症を治療するための物質および方法 | |
| CN114786659A (zh) | 用于治疗汉坦病毒感染的mek抑制剂 | |
| US20230338310A1 (en) | Anti-viral therapy | |
| WO2018210149A1 (zh) | 抑制多种病毒感染的药物及其联用 | |
| CN114377015B (zh) | 萘哌地尔在制备抗流感病毒药物中的应用 | |
| CN108721264B (zh) | 异克舒令在制备治疗或预防流感病毒感染的药物中的应用 | |
| Wu et al. | Pterostilbene inhibits influenza virus infection through interaction with NS1 protein | |
| CN115813929A (zh) | S63845在制备抗流感病毒感染药物中的应用 | |
| Reviriego | Laninamivir octanoate | |
| CN114469938A (zh) | 化合物bix02189在制备抗流感病毒药物中的应用 | |
| EA046313B1 (ru) | Лекарственные формы терапевтических препаратов от гриппа | |
| CN117503777A (zh) | 化合物在抗病毒中的应用 | |
| CA2999670A1 (en) | Ci-1040 for the treatment of viral diseases | |
| AU2018202283A1 (en) | Ci-1040 for the treatment of viral diseases |